Department of Thoracic Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Department of Rehabilitation, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Bioengineered. 2022 Jan;13(1):128-139. doi: 10.1080/21655979.2021.2009969.
It was to explore the clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted drugs combined with hyaluronic acid-gadolinium sesquioxide-nanoparticles (HA-Gd2O3-NPs) in non-small cell lung cancer (NSCLC). In this study, 70 patients with stage IV EGFR mutant NSCLC diagnosed in the First Affiliated Hospital of Jinzhou Medical University were selected. They were randomly divided into the combined group (35 cases) and the control group (35 cases). HA-Gd2O3-NPs were prepared by hydrothermal polymerization, and combined with EGFR-TKI in the clinical treatment of NSCLC. The results showed that HA-Gd2O3-NPs were spherical with a uniform particle size of about 124 nm. The NSCLC survival rate of the combined group was 37.2 ± 5.3% under 6 Gy X-ray irradiation, and that of the control group was 98.4 ± 12.6% under 6 Gy X-ray irradiation. The total effective rate of the control group (20%) was significantly lower than that of the study group (42.86%) ( 0.05). The one-year survival rate of the combined group (94%) was significantly higher than that of the control group (75%) ( 0.05). The median progression-free survival (PFS) in the control group was 8 months, and that in the combined group was 12 months, with statistical difference ( 0.05). EGFR-TKI targeted drugs combined with HA-Gd2O3-NPs can significantly improve the clinical efficacy of stage IV EGFR mutant NSCLC patients and benefit their survival.
探讨表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）靶向药物联合透明质酸-氧化钆纳米粒子（HA-Gd2O3-NPs）治疗非小细胞肺癌（NSCLC）的临床疗效和安全性。本研究选取锦州市第一附属医院诊断的Ⅳ期 EGFR 突变型 NSCLC 患者 70 例，随机分为联合组（35 例）和对照组（35 例）。采用水热聚合法制备 HA-Gd2O3-NPs，联合 EGFR-TKI 治疗 NSCLC。结果表明，HA-Gd2O3-NPs 呈球形，粒径均匀，约为 124nm。在 6Gy X 射线照射下，联合组 NSCLC 患者的生存率为 37.2%±5.3%，对照组为 98.4%±12.6%。对照组总有效率（20%）明显低于研究组（42.86%）（0.05）。联合组 1 年生存率（94%）明显高于对照组（75%）（0.05）。对照组无进展生存期（PFS）中位数为 8 个月，联合组为 12 个月，差异有统计学意义（0.05）。EGFR-TKI 靶向药物联合 HA-Gd2O3-NPs 可显著提高Ⅳ期 EGFR 突变型 NSCLC 患者的临床疗效，延长患者生存时间。
